Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd-Rüdiger Burmester

Showing results (141-150 of 171) with videos related to

Pageof 18
Sort By:
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialPhilip G Conaghan, Patrick Durez, Rieke E Alten, et al.
Annals of the Rheumatic Diseases|September 20, 2011
Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosusJan Broder Engler, Reinmar Undeutsch, Lutz Kloke, et al.
Clinical Rheumatology|December 16, 2014
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal DiseasesMustafa Al Maini, Femi Adelowo, Jamal Al Saleh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupusJens Y Humrich, Henner Morbach, Reinmar Undeutsch, et al.
Arthritis and Rheumatism|September 8, 2011
Origin and functional activity of the membrane-bound glucocorticoid receptorCindy Strehl, Timo Gaber, Mark Löwenberg, et al.
International Journal of Molecular Sciences|March 12, 2017
A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted PatientsPaula Hoff, Timo Gaber, Cindy Strehl, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Cellular & Molecular Immunology|February 12, 2013
Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma modelPaula Hoff, Patrick Maschmeyer, Timo Gaber, et al.
Pageof 18

Showing results (141-150 of 171) with videos related to

Sort By:
Pageof 18
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
Annals of the Rheumatic Diseases|August 24, 2012
Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trialPhilip G Conaghan, Patrick Durez, Rieke E Alten, et al.
Annals of the Rheumatic Diseases|September 20, 2011
Unmasking of autoreactive CD4 T cells by depletion of CD25 regulatory T cells in systemic lupus erythematosusJan Broder Engler, Reinmar Undeutsch, Lutz Kloke, et al.
Clinical Rheumatology|December 16, 2014
The global challenges and opportunities in the practice of rheumatology: white paper by the World Forum on Rheumatic and Musculoskeletal DiseasesMustafa Al Maini, Femi Adelowo, Jamal Al Saleh, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 1, 2017
A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid ArthritisMichael E Weinblatt, Clifton O Bingham, Gerd-Rüdiger Burmester, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 19, 2009
Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupusJens Y Humrich, Henner Morbach, Reinmar Undeutsch, et al.
Arthritis and Rheumatism|September 8, 2011
Origin and functional activity of the membrane-bound glucocorticoid receptorCindy Strehl, Timo Gaber, Mark Löwenberg, et al.
International Journal of Molecular Sciences|March 12, 2017
A Pronounced Inflammatory Activity Characterizes the Early Fracture Healing Phase in Immunologically Restricted PatientsPaula Hoff, Timo Gaber, Cindy Strehl, et al.
Clinical and Experimental Rheumatology|April 27, 2019
Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI)Thomas Dörner, Hendrik Schulze-Koops, Gerd-Rüdiger Burmester, et al.
Cellular & Molecular Immunology|February 12, 2013
Human immune cells' behavior and survival under bioenergetically restricted conditions in an in vitro fracture hematoma modelPaula Hoff, Patrick Maschmeyer, Timo Gaber, et al.
Pageof 18